Twelve shifting paradigms in diabetic renal disease and hypertension

Diabetes Research and Clinical Practice

Volumn 82, Issue SUPPL. 1, 2008, Pages

  Mogensen, Carl Erik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Diabetes; Hyperfiltration; Hypertension; Microalbuminuria; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SUBSTITUTION; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PERFUSION; METABOLIC REGULATION; MICROALBUMINURIA; MORTALITY; PROTEINURIA; REMISSION; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT;

ALBUMINURIA; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; PROGNOSIS;

EID: 55249106862     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.029     Document Type: Article

References (50)

1. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
2. Andersen N.H., Poulsen P.L., Knudsen S.T., Poulsen S.H., Eiskjaer H., Hansen K.W., et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diab. Care 28 (2005) 273-277
3. Basi S., and Lewis J.B. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am. J. Kidney Dis. 47 (2006) 927-946
4. Böhm M., Thoenes M., Danchin N., Bramlage P., La Puerta P., and Volpe M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individual: the i-SEARCH global study. J. Hypertens. 25 (2007) 2317-2324
5. Caramori M.L., Fioretto P., and Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J. Am. Soc. Nephrol. 17 (2006) 339-352
6. Casas J.P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A.D., et al. Effect of inhibitors of the rennin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
7. 2-microglobulin hyperexcretion in recent severe essential hypertension. J. Hypertens. 1 (1983) 45-51
8. De Jong P.E., and Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 66 (2004) 2109-2118
9. Hall P.M. Prevention of pregression in diabetic nephropathy. Diab. Spectr. 19 (2006) 18-24
10. Hansen K.W., Mau Pedersen M., Christensen C.K., Christiansen J.S., and Mogensen C.E. Normoalbuminuria ensures no reduction of renal function in Type 1 (insulin-dependent) diabetic patients. J. Intern. Med. 232 (1992) 161-167
11. Hovind P., Rossing P., Tarnow L., Smidt U.M., and Parving H.H. Prog. Diab. Nephropathy 59 (2001) 702-709
12. Gaede P., Lund-Andersen H., Parving H.-H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358 (2008) 580-591
13. Home P. Safety of very tight blood glucose control in type 2 diabetes. Br. Med. J. 336 (2008) 458-459
14. Jennings D.L., Kalus J.S., Coleman C.I., Manierski C., and Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diab. Med. 24 5 (2007) 486-493
15. Keane W.F., Zhang Z., Lyle P.A., Cooper M.E., de Zeeuw D., Grunfeld J.P., et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin. J. Am. Soc. Nephrol. 1 (2006) 761-767
16. Klausen K.P., Scharling H., and Jensen J.S. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J. Int. Med. 260 (2006) 231-237
17. Klausen K.P., Scharling H., Jensen G., and Jensen J.S. New definition of microalbuminuria in hypertensive subjects. Association with incident coronary heart disease and death. Hypertension 46 (2005) 33-37
18. Knudsen S.T., Andersen N.H., and Mogensen C.E. Ambulatory pulse pressure and progression of albuminuria in type 2 diabetes. Evidence provided. New questions emerge. Hypertension 48 (2006) 207-208
19. Knudsen S.T., Andersen N.H., Poulsen S.H., Eiskjær H., Hansen K.W., Helleberg K., et al. Pulse pressure lowering effect of dual blockade with Candesartan and Lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am. J. Hypertens. 21 2 (2008) 172-176
20. Mogensen C.E. Renal Dysfunction and Hypertension. In: Goldsten B.J., and Müller-Wieland D. (Eds). Type 2 Diabetes. Principles and Practice (2007), Informa Healthcare
21. C.E. Mogensen, Prediction of clinical diabetic nephropathy in type 1 diabetic patients: alternatives to microalbuminuria? Messages related to the microalbuminuria concept: 1990-2006, in: Robertson, R. (Ed.), Commentaries on Perspectives in Diabetes, vol. 1 (1988-1992), in: R. Paul Robertson (Ed.), American Diabetes Association 2006, 2006.
22. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310 (1984) 356-360
23. Mogensen C.E., and Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 311 (1984) 89-93
24. Mogensen C.E. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J. Int. Med. 254 (2003) 45-66
25. Mogensen C.E., and Poulsen P.L. Microalbuminuria, glycemic control, and blood pressure prediction outcome in diabetes type 1 and type 2. Kidney Int. 66 (2004) S40-S41
26. Mogensen C.E. Diabetic renal disease: the quest for normotension-and beyond. Diab. Med. 12 (1995) 756-769
27. Mogensen C.E. Renal function changes in diabetes. Diabetes 26 (1976) 872-879
28. Mogensen C.E. Pathophysiology of diabetic complications, Abnormal physiological processes in Kidney. In: Brownlee M. (Ed). Handbook of Diabetes vol. 4 (1981), Biochemical Pathology. Garland STPM Press, New York, London
29. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. 285 (1982) 685-688
30. Mogensen C.E., Chachati A., Christensen C.K., Close C.F., Deckert T., Hommel E., et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest. 9 (1985-1986) 85-95
31. Mogensen C.E., Schmitz A., and Christensen C.K. Comparative renal pathophysiology relevant to IDDM and NIDDM patients. Diab./Metab. Rev. 5 (1988) 453-483
32. Mogensen C.E. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42 (1999) 263-285
33. Mogensen C.E. Microalbuminuria, renal disease, metabolic syndrome and risks in diabetes. Diab. Metab. Syndr. Clin. Res. Rev. 1 (2007) 127-133
34. Mogensen C.E. ACE-inhibitors and antihypertensive treatment in diabetes: focus on microalbumininuria and macrovascular disease. JRAAS 1 (2000) 234-239
35. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., and Cooper M.E. Randomised controlled trial of dual blockade of the renin angiotensin system in hypertensive, microalbuminuric, non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. 321 (2000) 1440-1444
36. Mogensen C.E. Diabetic renal and hypertensive disease. In: Brunner H. (Ed). The Year in Hypertension vol. 6 (2006), Clinical Publishing, Oxford 73-83
37. Murussi M., Campagnolo N., Beck M.O., Gross L., and Silveiro S.P. High-normal levels of albuminuria predict the development of micro- and macroalbuminuria and increased mortality in Brazilian type 2 diabetic patients: an 8-year follow-up study. Diab. Med. 24 (2007) 1136-1142
38. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am. J. Kidney Dis. 39 (2) (Suppl. 1) (2002) S1-S66.
39. Ogawa S., Takeuchi K., Mori T., Nako K., Tsubono Y., and Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens. Res. 30 4 (2007) 325-334
40. Parving H.H., Andersen A.R., Smidt U.M., Hommel E., Mathiesen E.R., and Svendsen P.A. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br. Med. J. 294 (1987) 1443-1447
41. Parving H.H., Jensen HÆ, Mogensen C.E., and Evrin P.-E. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1 (1974) 1190-1192
42. Premaratne E., Macisaac R.J., Tsalamandris C., Panagiotopoulos S., Smith T., and Jerums G. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia 48 (2005) 2486-2493
43. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342 (2000) 143-145
44. Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H., Ishizaki M., et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N. Engl. J. Med. 313 26 (1985) 1617-1620
45. Tuttle K.R. Albuminuria reduction: the holy grail for kidney protection. Kidney Int. 72 (2007) 785-786
46. Watkins P.J., Blainey J.D., Brewer D.B., Fitzgerald M.G., Malins J.M., O'Sullivan D.J., et al. The natural history of diabetic renal disease. A follow-up study of a series of renal biopsies. Q. J. Med., New Ser., XLI 164 (1972) 437-456
47. Kuhn T.S. The Structure of Scientific Revolutions. 2nd edition (1970), The University of Chicago
48. In: Cortes P., and Mogensen C.E. (Eds). The Diabetic Kidney (2006), Humana Press, Totowa, New Jersey
49. In: Mogensen C.E. (Ed). The Kidney and Hypertension in Diabetes Mellitus (2004), Taylor & Francis, London, New York
50. In: Mogensen C.E. (Ed). Pharmacotherapy of Diabetes: New Developments (2007), Springer, New York